TMDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TransMedics Group Inc (TMDX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite the recent price drop, the company's strong financial performance, positive analyst sentiment, and innovative product offerings in the growing organ transplant market make it a compelling long-term investment opportunity.
The technical indicators are mixed. The MACD is positive and contracting, suggesting a potential bullish trend. RSI is neutral at 32.855, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its key support level of 130.828, which could act as a floor for the price. The recent price drop of -6.49% in the regular market and -2.19% in pre-market indicates short-term weakness but does not undermine the long-term potential.
Strong Q4 2025 financial performance with revenue up 32.18% YoY and net income up 1436.87% YoY.
Positive analyst sentiment with multiple price target increases, with the highest at $
Innovative and market-leading Organ Care System (OCS) with high organ utilization rates.
Expansion into European markets and focus on heart and lung clinical trials.
Dedicated transportation network to improve operational efficiency.
Recent insider selling activity, with a 100.84% increase in the last month.
Regulatory hurdles and high maintenance costs that could impact growth.
Short-term price weakness with a -6.49% drop in the regular market and -2.19% in pre-market.
Gross margin decline by -1.86% YoY in Q4 2025.
TransMedics reported strong financial results in Q4 2025, with revenue increasing to $160.76M (up 32.18% YoY), net income reaching $105.38M (up 1436.87% YoY), and EPS at $2.57 (up 1252.63% YoY). However, gross margin dropped slightly to 58.11% (down -1.86% YoY). The company also reported a significant tax benefit due to a valuation allowance, boosting net income.
Analyst sentiment is highly positive, with multiple price target increases ranging from $149 to $175. Analysts highlight strong financial performance, innovative product offerings, and growth potential in the organ transplant market. However, some analysts note potential challenges, including competition and regulatory hurdles.
